Institutional members access full text with Ovid®

Share this article on:

Goserelin Acetate as Treatment for Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study.

Asbury, Robert F. M.D.; Brunetto, Virginia L. M.A.; Lee, Roger B. M.D.; Reid, Gary M.D.; Rocereto, Thomas F. M.D.

American Journal of Clinical Oncology: December 2002 - Volume 25 - Issue 6 - pp 557-560
Article

This Gynecologic Oncology Group (GOG) study was designed to estimate the activity of goserelin acetate as treatment for advanced and recurrent endometrial carcinoma. Forty evaluable patients received monthly treatment with goserelin acetate at a dose of 3.6 mg, given subcutaneously. Standard GOG response and adverse effects criteria were used. The median age of patients was 71 years. Seventy-one percent of patients had received prior radiation therapy; 18% of patients were reported to have received prior progestational therapy for endometrial cancer. One patient had received prior chemotherapy. There were two complete responses (5%) and three partial responses (7%). One response occurred in a patient who previously did not respond to progestin therapy after having achieved a response. The overall response rate was 11% (95% CI: 4-27%). Median progression-free survival was 1.9 months and median overall survival was 7.3 months. No severe or life-threatening toxicities occurred because of goserelin. Deep venous thrombosis developed in two patients. This study confirmed the limited activity of goserelin acetate in endometrial carcinoma, with only one response in a patient previously treated with hormonal therapy. The activity is insufficient to warrant further study of the single agent at this time. Elucidation of the mechanism of action of this drug may allow more effective use in conjunction with other agents in the future.

From Interlakes Oncology Hematology, P.C. (R.F.A.), Rochester, New York; Gynecologic Oncology Group, Roswell Park Cancer Institute (V.L.B.), Buffalo, New York; Division of Gynecologic Oncology, University of Washington, Seattle, Washington (R.B.L.); Division of Gynecologic Oncology, Oregon Health Sciences University, Portland, Oregon (R.B.L.); Gynecologic Oncology, Grant/Riverside Methodist Hospitals (G.R.), Columbus, Ohio; and Cooper Hospital/University Medical Center (T.F.R.), Camden, New Jersey, U.S.A.

The following are Gynecologic Oncology Group institutions that participated in this study: Abington Memorial Hospital, Brookview Research Inc., Case Western Reserve University, Cleveland Clinic Foundation, Columbus Cancer Council, Cooper Hospital University, Duke University, Emory University, M.S. Hershey Medical Center, Indiana University Medical Center, Thomas Jefferson University Hospital, Medical University of South Carolina, Southwest Medical Center of Texas, Tacoma General Hospital, Tampa Bay Cancer Consortium, University of California Medical Center at Irvine, University of Iowa, University of Kentucky, University of Oklahoma, University of Virginia Health Sciences Center, Wake Forest University School of Medicine, Washington University, Wayne State University, Womens Cancer Center.

This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical Office (CA 37517).

Address correspondence to Dr. Robert F. Asbury, Interlakes Oncology Hematology, P.C., 211 White Spruce Boulevard, Rochester, New York 14623, U.S.A. Address reprint requests to GOG Administrative Office, Suite 1945, 1234 Market Street, Philadelphia, PA 19107, U.S.A.

© 2002 Lippincott Williams & Wilkins, Inc.